Medical devices, healthcare technology and the business of care
PMA approval · P040045

VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER

Vistakon, Division of Johnson & Johnson Vision Car · Decision date Dec 20, 2005

MEDTECHLEDGER EXPLANATIONP040045

What did the FDA approve?

FDA approved the Vistakon senofilcon A contact lens platform on December 20, 2005. The approval covers spherical, multifocal, toric, and multifocal-toric designs for refractive ametropia in phakic or aphakic persons with non-diseased eyes, with astigmatism limits of 1.00D or less for spherical, 0.75D or less for multifocal, and 10.00D or less for toric and multifocal-toric lenses.

The lenses may be prescribed for single-use disposable wear or frequent/planned replacement wear using chemical disinfection only. Daily wear and extended wear up to 6 nights/7 days of continuous wear are permitted, with an initial daily wear evaluation recommended before gradual introduction of extended wear. The UV blocking feature is described as helping protect against transmission of harmful UV radiation to the cornea and into the eye.

FDA approval order statement

APPROVAL FOR THE VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER. THE DEVICE IS INDICATED FOR USE AS FOLLOWS: THE VISTAKON (SENOFILCON A) SOFT CONTACT LENS (SPHERICAL) IS INDICATED FOR THE OPTICAL CORRECTION OF REFRACTIVE AMETROPIA (MYOPIA AND HYPEROPIA) IN PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES WHO HAVE 1.00D OR LESS OF ASTIGMATISM. THE VISTAKON (SENOFILCON A) MULTIFOCAL SOFT CONTACT LENS IS INDICATED FOR THE OPTICAL CORRECTION OF DISTANCE AND NEAR VISION IN PRESBYOPIC, PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES WHO MAY HAVE 0.75D OF ASTIGMATISM OR LESS. THE VISTAKON (SENOFILCON A) TORIC SOFT CONTACT LENS IS INDICATED FOR THE OPTICAL CORRECTION OF VISUAL ACUITY IN PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES THAT ARE HYPEROPIC OR MYOPIC AND MAY HAVE 10.00D OF ASTIGMATISM OR LESS. THE VISTAKON (SENOFILCON A) MULTIFOCAL-TORIC SOFT CONTACT LENS IS INDICATED FOR THE OPTICAL CORRECTION OF DISTANCE AND NEAR IN PRESBYOPIC PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES WHO MAY HAVE 10.00D OF ASTIGMATISM OR LESS. THE VISTAKON (SENOFILCON A) UV BLOCKING SOFT CONTACT LENS HELP PROTECT AGAINST TRANSMISSION OF HARMFUL UV RADIATION TO THE CORNEA AND INTO THE EYE. EYE CARE PROFESSIONALS MAY PRESCRIBE THE LENSES EITHER FOR SINGLE-USE DISPOSABLE WEAR OR FREQUENT/PLANNED REPLACEMENT WEAR WITH CLEANING, DISINFECTION AND SCHEDULED REPLACEMENT. WHEN PRESCRIBED FOR FREQUENT/PLANNED REPLACEMENT WEAR THE LENSES MAY BE CLEANED AND DISINFECTED USING A CHEMICAL DISINFECTION SYSTEM ONLY. VISTAKON (SENOFILCON A) CONTACT LENSES MAY BE PRESCRIBED FOR DAILY WEAR AND EXTENDED WEAR FOR UP TO 6 NIGHTS/7 DAYS OF CONTINUOUS WEAR. IT IS RECOMMENDED THAT THE CONTACT LENS WEARER FIRST BE EVALUATED ON A DAILY WEAR SCHEDULE. IF SUCCESSFUL, THEN A GRADUAL INTRODUCTION OF EXTENDED WEAR CAN BE FOLLOWED AS DETERMINED BY THE PRESCRIBING EYE CARE PROFESSIONAL.
Regulatory pathway
Original PMA
Clinical specialty
Ophthalmic
Decision date
Dec 20, 2005

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P040045
Regulatory pathway
Premarket approval application
Product code
LPM
Decision code
APPR
Decision date
Dec 20, 2005
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lenses, soft contact, extended wear.

Product code
LPM
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P040045 received

    Application receipt date recorded by FDA.

  2. P040045 · FDA decision

    APPR

  3. P040045/S145 · Related supplement

    VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER

  4. P040045/S146 · Related supplement

    VISTAKON (SENOFILCON A) Brand Contact Lenses

  5. P040045/S147 · Related supplement

    VISTAKON (senofilcon A) Brand Contact Lenses

Timeline entries are records held by MedtechLedger for P040045. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040045

Explore the linked device profile

Other records with product code LPM

Product / regulatory recordCompanyPathwayDecision dateSource
Bausch and Lomb, Inc.,PMA supplementSep 14, 2026FDA
CooperVision, Inc.PMA supplementSep 2, 2026FDA
Bausch and Lomb, Inc.,PMA approvalApr 30, 2018FDA
CooperVision, Inc.PMA approvalNov 19, 2008FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Vistakon, Division of Johnson & Johnson Vision Car

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7500 Centurion Pkwy., Suite 100 - Erca, Jacksonville, FL, 32256

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records